Loading...
XTSE
HBP
Market cap60mUSD
Aug 13, Last price  
1.12CAD
1D
14.29%
1Q
15.46%
Jan 2017
-27.27%
Name

Helix Biopharma Corp

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-16.04%
Rev. gr., 5y
%
Revenues
0k
3,424,0003,591,0003,841,0004,434,0004,532,0004,260,000000000000000
Net income
-9m
L+47.28%
-7,674,000-6,964,000-14,102,000-14,469,000-11,348,000-17,440,000-1,570,000-8,701,000-8,743,000-9,682,000-10,073,000-8,654,000-7,527,000-9,010,000-7,911,000-6,080,000-6,290,000-9,264,000
CFO
-5m
L-5.57%
-6,079,000-6,997,000-13,157,000-12,193,000-10,339,000-14,112,000-7,814,000-7,692,000-8,488,000-8,853,000-9,295,000-7,524,000-5,531,000-10,826,000-9,304,000-6,509,000-5,527,000-5,219,000

Profile

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
URL
https://www.helixbiopharma.com/
IPO date
Jun 03, 1996
Employees
7
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑072023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑07
Income
Revenues
Cost of revenue
6,109
5,593
Unusual Expense (Income)
NOPBT
(6,109)
(5,593)
NOPBT Margin
Operating Taxes
(132)
14
Tax Rate
NOPAT
(5,977)
(5,607)
Net income
(9,264)
47.28%
(6,290)
3.45%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,506
4,151
BB yield
-53.81%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(1,081)
(808)
Cash flow
Cash from operating activities
(5,219)
(5,527)
CAPEX
(14)
(10)
Cash from investing activities
(14)
(5)
Cash from financing activities
5,506
3,088
FCF
(6,732)
(4,727)
Balance
Cash
1,081
808
Long term investments
Excess cash
1,081
808
Stockholders' equity
(52,099)
(44,982)
Invested Capital
52,009
44,137
ROIC
ROCE
6,787.78%
661.89%
EV
Common stock shares outstanding
44,486
38,646
Price
0.23
 
Market cap
10,232
 
EV
9,151
EBITDA
(6,095)
(5,580)
EV/EBITDA
Interest
7
14
Interest/NOPBT